|
Anemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Anemia resulting from the reduced expression of erythropoietin (EPO) is a common complication of patients with chronic kidney diseases (CKD).
|
28625716 |
2017 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
CTD_human |
High dose of erythropoietin in management of interferon/ribavirin induced anemia.
|
18265628 |
2007 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
These results suggest that impaired production of Epo may be a direct effect of HIV-1 infection possibly contributing to anemia in AIDS.
|
8390370 |
1993 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Accelerating Epo production in hepatocytes is one plausible therapeutic strategy for treating anemia caused by kidney diseases.
|
26012551 |
2015 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
CTD_human |
Testosterone membrane-initiated action in breast cancer cells: Interaction with the androgen signaling pathway and EPOR.
|
20189893 |
2010 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
The recombinant form of human erythropoietin is in clinical use for the prevention and treatment of anemia that is associated with cancer and its treatment with chemoradiation therapy.
|
15467711 |
2005 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
The transplantation of polymer encapsulated myoblasts genetically engineered to secrete erythropoietin (Epo) may obviate the need for repeated parenteral administration of recombinant Epo as a treatment for chronic renal failure, cancer or AIDS-associated anemia.
|
10326023 |
1998 |
|
Anemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Proinflammatory cytokine, mainly IL-6, which are released by both tumor and immune cells, play a pivotal action in CRA etiopathogenesis: they promote alterations in erythroid progenitor proliferation, erythropoietin (EPO) production, survival of circulating erythrocytes, iron balance, redox status, and energy metabolism, all of which can lead to anemia.
|
30294279 |
2018 |
|
Anemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Hypoxia-regulated system of Epo gene expression constructed by fusing Epo to the HRE/CMV promoter and delivered by plasmid intramuscular injection may provide a long-term and stable Epo expression and secretion in vivo to correct the anemia in adenine-induced uremic rats.
|
22990115 |
2012 |
|
Anemia
|
0.500 |
Therapeutic
|
disease |
CTD_human |
Testosterone membrane-initiated action in breast cancer cells: Interaction with the androgen signaling pathway and EPOR.
|
20189893 |
2010 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
CTD_human |
Patients with esophagogastric adenocarcinoma who experienced anemia (hemoglobin < 12 g/dL) during neoadjuvant treatment received erythropoietin 10,000 IE subcutaneously three times a week.
|
16798232 |
2006 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Specific binding of erythropoietin to spleen cells infected with the anemia strain of Friend virus.
|
6095306 |
1984 |
|
Anemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The anemia of the newborn induces erythropoietin expression in the developing mouse retina.
|
20463184 |
2010 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that combination Fe + EPO therapy is effective in partially reversing ICU anemia when administered after the phase of acute inflammation.
|
28452907 |
2017 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Erythropoiesis-stimulating agents (ESAs) are man-made forms of erythropoietin used in the treatment of anemia.
|
30097240 |
2018 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Erythropoietin is used in a few patients with anaemia to overcome functional iron deficiency, and blood transfusion is being restricted to refractory cases or acute life-threatening situations.
|
30544934 |
2018 |
|
Anemia
|
0.500 |
Therapeutic
|
disease |
CTD_human |
We compared blood pressure after three different methods of partial correction of anemia in hemodialysis patients with similar baseline hematocrits (erythropoietin n = 12, intravenous iron alone n = 10, androgens n = 9).
|
1516988 |
1992 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin.
|
17559739 |
2007 |
|
Anemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The therapy for anemia evaluated in the most studies was erythropoietin-stimulating agents (77.7% of studies).
|
30100259 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Iron deficiency is a common etiology of anemia that causes suboptimal response to erythropoietin therapy in hemodialysis (HD) patients.
|
31679114 |
2020 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Erythropoiesis-stimulating agents, such as recombinant human erythropoietin, are commonly used for the treatment of anemia in patients with chronic kidney disease (CKD).
|
29296077 |
2018 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Epoetin-α reduced RBC transfusions and increased the time-to-first-transfusion compared with placebo.Thus, epoetin-α significantly improved anemia outcomes in low-risk MDS.
|
29895954 |
2018 |
|
Anemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The effectiveness of biosimilar epoetin alfa (Binocrit<sup>®</sup>, Sandoz) to correct anemia in lower-risk MDS patients has also been demonstrated in a retrospective, single-center, observational study.
|
31005849 |
2019 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recombinant human erythropoietin (Epo) supplementation is one of the methods for treating anemia.
|
27903235 |
2017 |
|
Anemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Erythropoietin (EPO) has been used to treat anemia of cancer patients, because it stimulates erythropoiesis.
|
28247960 |
2017 |